Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
P/E ratio for Amicus Therapeutics, Inc. (FOLD)
P/E ratio as of 2023: -27.63
According to Amicus Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -27.63. At the end of 2022 the company had a P/E ratio of -14.92.
P/E ratio history for Amicus Therapeutics, Inc. from 2003 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -27.63 |
| 2022 | -14.92 |
| 2021 | -12.52 |
| 2020 | -21.59 |
| 2019 | -6.57 |
| 2018 | -5.10 |
| 2017 | -7.77 |
| 2016 | -3.34 |
| 2015 | -8.07 |
| 2014 | -8.99 |
| 2013 | -2.02 |
| 2012 | -2.50 |
| 2011 | -2.68 |
| 2010 | -2.37 |
| 2009 | -13.68 |
| 2008 | -4.56 |
| 2007 | -3.46 |
| 2006 | -0.23 |
| 2005 | -0.30 |
| 2004 | -0.50 |
| 2003 | -0.66 |